Clinical trials: Relapsed Cancer
CAR, Refractory Acute Lymphoblastic Leukemia
ThisCART19A Bridging to alloHSCT for R/R B-ALL
This is a phase 1, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) bridging to HSCT in patients with refractory or relapsed B cell acute lymphoblastic leukemia (r/r…
- Conditions
- CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL
- Trial name
- NCT05679687
- Testing
- Treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD33 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05445765
- Testing
- anti-CD33 CAR T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- iCell Gene Therapeutics
T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid…
- Conditions
- T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04823091
- Testing
- Fludarabine + Cyclophosphamide + CAR7-T Cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Refractory Tumors, Malignant Tumors
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
Long term survival can now be achieved in 75% of cases of pediatric cancers. However, some types of tumors (ie CNS tumors) or advanced stages (metastatic sarcomas/neuroblastomas) cannot be cured by any treatment.
- Trial name
- NCT00412503
- Testing
- Topotecan, Temozolomide
- Where
- France
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Sarcoma, Osteosarcoma
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with…
- Trial name
- NCT07725380
- Testing
- Domatinostat, Sirolimus
- Where
- 4 sites in United States
- Volunteers
- 74 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Unresectable, Locally Advanced
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in…
- Conditions
- Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
- Trial name
- DAHLIA (NCT06678659)
- Testing
- REC-1245
- Where
- 7 sites in United States, Canada
- Volunteers
- 170 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Acute Myeloid Leukemia (AML)
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children.
- Trial name
- NCT06679582
- Testing
- Luveltamab tazevibulin
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 1 people
- Sponsor
- Sutro Biopharma, Inc.
Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
- Trial name
- NCT06179524
- Testing
- CAR-T-19 cell injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Yongtai Ruike Biotechnology Company Ltd
Extranodal NK/T-cell Lymphoma
Tofacitinib Combined With Chidamide in R/R ENKTCL
This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.
- Trial name
- NCT03598959
- Testing
- tofacitinib, chidamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Medulloblastoma, Medulloblastoma, Childhood
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken…
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent, Ependymoma
- Trial name
- PNOC027 (NCT05057702)
- Testing
- Specialized Tumor Board Treatment Plan, Combinations
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00101231
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, T-Cell
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
This study is an open and prospective clinical study, taking patients with relapsed or refractory CD7+ lymphoma as the test subjects, in order to evaluate the safety and efficacy of Senl-T7 CAR-T for patients with CD7+ lymphoma.
- Trial name
- NCT04928105
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Prostate Cancer
Effectiveness of Localized Prostate Cancer Treatments
The purpose of this study is to evaluate the effectiveness of the three most established primary treatments for patients with clinically localized prostate cancer (radical prostatectomy, external-beam radiotherapy, and prostate…
- Trial name
- E-PROSTCaT (NCT01492751)
- Testing
- Quality of life assessment and Clinical evaluation, Radical retropubic prostatectomy surgery, External beam radiotherapy
- Where
- 10 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Fundacion IMIM
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Leukemia, Myelodysplastic Syndromes
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
Valproic acid is a medication that is currently used in the prevention of seizures, bipolar disorder, and migraine headaches. Researchers hope that it may improve the effects of decitabine.
- Trial name
- NCT00075010
- Testing
- Decitabine, Valproic acid
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
MIBG for Refractory Neuroblastoma and Pheochromocytoma
This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are…
- Trial name
- NCT01850888
- Testing
- 131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Rhabdomyosarcomas, Neoplasms, Connective and Soft Tissue
Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
This is a phase II study to determine the antitumor activity of Vinorelbine and Cyclofosfamide association among patients with refractory tumours or in relapse with rhabdomyosarcomas and other soft tissue tumours, Ewing tumours…
- Conditions
- Rhabdomyosarcomas, Neoplasms, Connective and Soft Tissue, Ewing Tumor, Osteosarcomas
- Trial name
- NCT00180947
- Testing
- Vinorelbine, cyclofosfamide
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Unspecified Childhood Solid Tumor, Protocol Specific
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of aflibercept in treating young patients with relapsed or refractory solid tumors. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00622414
- Testing
- ziv-aflibercept
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Monocentric, phase I study for advanced sarcoma with adoptive immunotherapy with Cytokine-Induced Killer (CIK). In the first part of the study Patient's' peripheral blood will be collected and CIK cell expansion and storage will…
- Trial name
- CAST (NCT03782363)
- Testing
- Autologous CIK Dose level 1, Autologous CIK Dose level 2, Autologous CIK Dose level 3
- Where
- Italy
- Sponsor
- Italian Sarcoma Group
Neuroblastoma
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
The purpose of this study is to find out if an antibody called Humanized 3F8 (Hu3F8) combined with granulocyte- macrophage colony stimulating factor (GM-CSF) is safe for treating neuroblastoma.
- Trial name
- NCT01757626
- Testing
- Hu3F8 With GM-CSF
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.